menu
    • menu
    [{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Belrestotug","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Iteos Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Belrestotug","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ GSK"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Belrestotug","moa":"TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Belrestotug","moa":"TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Belrestotug","moa":"TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Belrestotug","moa":"TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Belrestotug","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Iteos Therapeutics \/ GSK"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Minister Of Economy And Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ Minister Of Economy And Research","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ Minister Of Economy And Research"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"EOS-850","moa":"A2AR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Iteos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Belrestotug","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Iteos Therapeutics \/ GSK"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Belrestotug","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Iteos Therapeutics \/ GSK"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Belrestotug","moa":"||TIGIT","graph1":"Oncology","graph2":"Phase III","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Iteos Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Iteos Therapeutics \/ GSK"},{"orgOrder":0,"company":"Iteos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EOS-984","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Iteos Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Iteos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Iteos Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Iteos Therapeutics

    Menu

    Iteos Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belrestotug,Dostarlimab,GSK6097608

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : RA Capital Management

                            Deal Size : $120.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            iTeos Therapeutics Announces $120 Million Registered Direct Offering

                            Details : The net proceeds from the financing are used to advance the clinical development of EOS-448 (belrestotug) in combination with GSK6097608 and Dostarlimab for non-small cell lung cancer.

                            Product Name : EOS-448

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            October 05, 2024

                            Lead Product(s) : Belrestotug,Dostarlimab,GSK6097608

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : RA Capital Management

                            Deal Size : $120.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belrestotug,Dostarlimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            iTeos Reports Positive Objective Response Rate in GALAXIES Lung-201 Study

                            Details : EOS-448 (belrestotug, TIGIT antibody) with dostarlimab is being investigated for previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.

                            Product Name : EOS-448

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 14, 2024

                            Lead Product(s) : Belrestotug,Dostarlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belrestotug,Dostarlimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : GSK

                            Deal Size : $2,075.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            iTeos Doses First Patient in GALAXIES Lung-301 Phase 3, Earns $35M from GSK

                            Details : The collaboration aims to advance the clinical development of late-stage product EOS-448 (belrestotug) in combination with Dostarlimab for the treatment of PD-L1 high Non-small Cell Lung Cancer.

                            Product Name : EOS-448

                            Product Type : Antibody

                            Upfront Cash : $625.0 million

                            August 07, 2024

                            Lead Product(s) : Belrestotug,Dostarlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : GSK

                            Deal Size : $2,075.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EOS-984

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            iTeos Presents EOS-984 Preclinical Data Showing T Cell Activity Restoration

                            Details : EOS-984 is a potential first-in-class small molecule inhibitor targeting the equilibrative nucleoside transporter 1 (ENT1). It is being evaluated for the treatment of triple negative breast cancer.

                            Product Name : EOS-984

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 04, 2024

                            Lead Product(s) : EOS-984

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belrestotug,Dostarlimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            iTeos and GSK Launch Phase 3 Study on Belrestotug and Dostarlimab in Lung Cancer

                            Details : Antibody combination, EOS-448 (belrestotug) with dostarlimab is being investigated in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected NSCLC.

                            Product Name : EOS-448

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 17, 2024

                            Lead Product(s) : Belrestotug,Dostarlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belrestotug,Dostarlimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022

                            Details : In preclinical studies and in blood samples from patients with cancer, treatment with EOS-448 (GSK4428859A) results reduction in suppressive and exhausted immune cell populations, indicating engagement of FcγR, an essential component in many immune syst...

                            Product Name : EOS-448

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            August 04, 2022

                            Lead Product(s) : Belrestotug,Dostarlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belrestotug

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            iTeos Therapeutics Announces New Preliminary Data Indicating Clinical Activity with its Anti-TIGIT Antibody, E...

                            Details : Initial data from the Phase 1 dose escalation part of the Phase 1/2a trial in adult patients with advanced solid tumors indicated EOS-448 was generally well tolerated with no dose-limiting toxicities observed.

                            Product Name : EOS-448

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 04, 2021

                            Lead Product(s) : Belrestotug

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belrestotug,Dostarlimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : GSK

                            Deal Size : $2,075.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GSK Pays Up Big for Rights To TIGIT-Targeted Cancer Immunotherapy from Iteos

                            Details : The addition of EOS-448 results in GSK being the only company with antibodies targeting all three known checkpoints – TIGIT (via EOS-448), CD96 (via GSK’608), and PVRIG (via GSK’562).

                            Product Name : EOS-448

                            Product Type : Antibody

                            Upfront Cash : $625.0 million

                            June 14, 2021

                            Lead Product(s) : Belrestotug,Dostarlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : GSK

                            Deal Size : $2,075.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EOS-850

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Phase 1/2 oncology biotech iTeos Therapeutics files for a $100 million IPO

                            Details : The company's lead candidate EOS-850, a highly selective small molecule antagonist of the adenosine A2a receptor (A2AR), is in an open-label Phase 1/2 clinical trial in adult patients with advanced solid tumors, with initial data expected in the 1H 2021.

                            Product Name : EOS-850

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 24, 2020

                            Lead Product(s) : EOS-850

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Iteos Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belrestotug

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            iTeos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annu...

                            Details : EOS-448 is being investigated in a Phase 1/2a clinical trial in advanced solid tumors and the dose escalation portion of the trial was initiated in February 2020.

                            Product Name : EOS-448

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 22, 2020

                            Lead Product(s) : Belrestotug

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth